Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide and Denosumab in Postmenopausal Osteoporosis
NCT04026256Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2019
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in postmenopausal osteoporosis comparing Teriparatide only, Denosumab only and Denosumab and teriparatide (3 arms). Primary endpoint: Cancellous Bone Formation Rate at 3 months. Started Sep 2019; status: completed.
02
Drugs
teriparatidedenosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT04026256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04026256.